32 results about "Multiple organ dysfunction syndrome" patented technology

A method and apparatus (100) for providing continuous analysis and display of the variability of multiple patient parameters monitored by multiple beside monitors (106a-106c) for each patient (102). Each monitor is connected to a patient interface and to a patient data storage unit (115) and a processor (113). Each monitored patient parameter is measured in real-time. Data artifacts are removed, and variability analysis is performed based upon a selected period of observation. Variability analysis yields variability of the patient parameters, which represents a degree to which the patient parameters fluctuate over time, to provide diagnostic information particularly useful in the detection, prevention and treatment of multiple organ dysfunction syndrome (MODS).

An oligonucleotide with a nucleotide sequence of 5′-cctcctcctcctcctcctcctcct-3′ (SEQ ID NO: 1) inhibits proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus and serum from SLE patients, and rescues the mice from cytokine-mediated lethal shock. This oligonucleotide can be used as a remedy for the treatment of systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and other immune-mediated disorders.

Drug compositions containing a substituted diamine compound represented by formula (1):Q1-Q2-r-N(R1)-Q3-N(R2)  (1)wherein Q3 represents the following groupwherein Q5 represents an alkylene group having 4 carbon atoms, R3 represents a hydrogen atom, and R4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and / or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

The inhibitory oligonucleotides with partial phosphorothioation with reduced toxicity strongly block NF-kB activation induced by TLR9 agonists and TLR7 / 8 agonists. The production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa), is inhibited by the inhibitory-oligonucleotides. Interferon (IFN) production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-oligonucleotides. These oligonucleotides can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and inflammatory cytokine-mediated inflammatory disease.

Methods of preventing and / or treating ischemia, organ dysfunction and / or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction / failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

The invention provides an establishment method of an animal model for acute Stanford A-type aortic dissection (AD) accompanied with MODS (multiple organ dysfunction syndrome), a use of emodin for preparing a medicine for treating acute Stanford A-type AD accompanied with MODS as well as a viscera protective agent for acute Stanford A-type AD accompanied with MODS. In the invention, an AD surgery method is improved and meanwhile manually controlled hypertension is formed by continuously pumping adrenaline into veins so as to promote expansion of the AD stripping range and accelerate disease progression, thus acute Stanford A-type AD accompanied with MODS can be rapidly formed so as to successfully make the model. The animal model for acute Stanford A-type AD accompanied with MODS creates conditions for further deep research in application foundation and intervention treatment.

The invention relates to a use of an aidi preparation in the preparation of medicaments for treating senile diseases, in particular to a use of an aidi preparation in the preparation of medicaments for treating multiple organ dysfunction syndrome in the elderly, wherein the aidi preparation comprises four medicines, namely ginseng, blister beetle, membranous milkvetch root and manyprickle acanto-panax root; a new treatment way is provided for the senile diseases, and the clinical application of the aidi preparation is further expanded.

The invention relates to a human high density lipoprotein and product, preparation process and use thereof, wherein the apo AI content in the human high density lipoprotein is 77-89%. The preparation process comprises using blood plasma as raw material, extracting HDL through segregation and purification steps. The prepared human high density lipoprotein and products produced thereby can be applied to the preparation for medicaments for treating multiple organ dysfunction syndrome (MODS), cardiovascular system diseases such as atherosclerosis (AS).

The invention relates to tyrosine hydroxylase inhibitors for the treatment of intestinal hyperpermeability, and provides methods, compositions and kits for the treatment of intestinal hyperpermeability in a subject in need thereof, the intestinal hyperpermeability includes conditions such as hyperglycemia and conditions such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV / AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, and the like. The medicine can be used for treating basic diseases such as ankylosing spondylitis, non-alcoholic fatty liver disease, alcoholic cirrhosis, environmental intestinal lesion or malignant dystrophy.

The inhibitory oligonucleotides (ODNs) which strongly block NF-κB activation induced by TLR9 agonists and TLR7 agonists are provided. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-ODNs. Interferon production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-ODNs. These ODNs can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating septic shock and accompanying multi-organ dysfunction syndrome. The traditional Chinese medicine composition is prepared from the combination of red ginseng, radix aconiti lateralis preparata, ligusticum wallichii, salvia miltiorrhiza, pulsatilla chinensis, radix aucklandiae, radix ophiopogonis and crocus sativus which synergistically act to play the effects of effectively clearing heat and removing toxicity, strengthening healthy energy and tonifying Qi, and promoting blood circulation to remove blood stasis so as to reach the purpose of treating septic shock and accompanying multi-organ dysfunction syndrome. The traditional Chinese medicine composition is accurate in treatment effect, free of toxic and side effects, outstanding in treatment effect and high in potential clinical application value, and reaches total effective rate exceeding 85.00%.

Hypoxia is diagnosed through measurements of oxygen saturation. Some examples of hypoxia conditions that may be diagnosed include peripheral vascular disease, multiple organ dysfunction syndrome, ischemia, hypotension, and arteriosclerosis. In a specific implementation, a hypoxia condition is diagnosed based on changes in oxygen saturation in tissue. Ischemia is induced, and then measurements of changes in oxygen saturation in tissue are made. Based on changes in oxygen saturation, a diagnosis is provided of whether a patient has or does not have a hypoxia condition.